Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 04 04:00PM ET
5.53
Dollar change
+0.20
Percentage change
3.75
%
IndexRUT P/E7.67 EPS (ttm)0.72 Insider Own17.43% Shs Outstand54.54M Perf Week-1.25%
Market Cap302.08M Forward P/E- EPS next Y-1.60 Insider Trans-0.18% Shs Float45.11M Perf Month-7.37%
Income25.88M PEG- EPS next Q-0.37 Inst Own64.63% Short Float5.66% Perf Quarter-19.03%
Sales163.78M P/S1.84 EPS this Y-131.10% Inst Trans-4.74% Short Ratio5.71 Perf Half Y-33.37%
Book/sh6.06 P/B0.91 EPS next Y-72.68% ROA7.18% Short Interest2.55M Perf Year-26.85%
Cash/sh6.32 P/C0.87 EPS next 5Y- ROE10.22% 52W Range4.99 - 10.66 Perf YTD-2.47%
Dividend Est.- P/FCF- EPS past 5Y- ROI7.02% 52W High-48.12% Beta0.95
Dividend TTM- Quick Ratio8.45 Sales past 5Y126.57% Gross Margin96.91% 52W Low10.82% ATR (14)0.30
Dividend Ex-Date- Current Ratio8.45 EPS Y/Y TTM-43.86% Oper. Margin5.54% RSI (14)48.25 Volatility5.03% 5.17%
Employees162 Debt/Eq0.14 Sales Y/Y TTM3.40% Profit Margin15.80% Recom1.08 Target Price17.10
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q73.53% Payout0.00% Rel Volume0.52 Prev Close5.33
Sales Surprise110.46% EPS Surprise64.03% Sales Q/Q433.79% EarningsNov 12 AMC Avg Volume447.22K Price5.53
SMA201.24% SMA50-4.67% SMA200-21.61% Trades Volume231,171 Change3.75%
Date Action Analyst Rating Change Price Target Change
Jan-10-25Initiated Cantor Fitzgerald Overweight
Dec-02-24Initiated Citigroup Buy $12
Nov-29-24Resumed Wedbush Outperform $7 → $11
Oct-16-24Initiated Leerink Partners Outperform $15
Mar-26-24Initiated Guggenheim Buy $22
Mar-19-24Initiated H.C. Wainwright Buy $30
Mar-07-24Initiated Citigroup Buy $16
Jan-02-24Upgrade Wells Fargo Equal Weight → Overweight $14
May-10-23Initiated Truist Buy $18
Mar-10-23Initiated Oppenheimer Outperform $14
Jan-30-25 12:00PM
Dec-29-24 06:22AM
Dec-03-24 09:55AM
Nov-30-24 06:55AM
Nov-20-24 07:00AM
08:37AM Loading…
Nov-13-24 08:37AM
02:18AM
Nov-12-24 05:20PM
04:19PM
04:01PM
Nov-06-24 07:00AM
Nov-05-24 07:00AM
Oct-28-24 10:01AM
Oct-07-24 05:16AM
Sep-16-24 07:00AM
08:00AM Loading…
Sep-05-24 08:00AM
Aug-29-24 04:01PM
07:00AM
Aug-07-24 07:00AM
Aug-06-24 05:15PM
04:11PM
04:01PM
Jul-30-24 07:00AM
Jul-23-24 04:01PM
Jul-09-24 04:01PM
Jun-13-24 04:01PM
07:00AM
May-16-24 07:00AM
May-14-24 08:16AM
06:27AM
03:03AM Loading…
03:03AM
May-13-24 08:56PM
05:10PM
04:09PM
04:01PM
May-08-24 06:00AM
May-06-24 07:00AM
Apr-22-24 04:30PM
Apr-16-24 07:00AM
Mar-30-24 03:00AM
Mar-26-24 04:01PM
Mar-13-24 07:00AM
Mar-09-24 01:09PM
Feb-29-24 11:09AM
09:54AM
Feb-28-24 04:41PM
04:32PM
04:01PM
Feb-26-24 07:00AM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
Feb-07-24 07:00AM
Jan-11-24 10:09PM
Jan-04-24 10:45PM
04:14PM
Jan-03-24 11:15AM
07:00AM
Jan-02-24 04:07PM
01:51PM
10:46AM
07:36AM
07:14AM
07:14AM
07:09AM
07:00AM
Dec-17-23 12:03PM
Dec-08-23 10:13AM
Dec-07-23 06:10AM
Dec-06-23 07:00AM
Nov-07-23 10:16AM
Nov-06-23 05:22PM
04:17PM
04:01PM
Oct-30-23 07:00AM
Sep-25-23 07:00AM
Sep-07-23 04:01PM
Aug-30-23 07:00AM
Aug-22-23 08:14AM
Aug-08-23 04:01PM
Aug-07-23 08:00AM
Aug-03-23 08:25AM
07:17AM
07:00AM
Aug-02-23 07:00AM
Jul-27-23 07:00AM
Jul-14-23 05:40AM
Jul-11-23 08:53PM
04:01PM
Jul-10-23 08:00AM
Jun-21-23 04:49AM
Jun-15-23 06:30AM
Jun-01-23 07:52PM
07:00AM
May-25-23 12:29PM
May-18-23 06:00AM
May-09-23 08:35AM
07:37AM
07:00AM
06:55AM
May-05-23 06:08AM
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swartz RobinCOO & CBOJan 14 '25Sale5.093,08715,713109,241Jan 15 04:18 PM
Carter Todd AlfredChief Scientific OfficerJan 14 '25Sale5.131,1916,11086,436Jan 15 04:17 PM
Swartz RobinOfficerJan 14 '25Proposed Sale5.093,08715,721Jan 14 03:17 PM
Carter Todd AlfredOfficerJan 14 '25Proposed Sale5.131,1916,106Jan 14 03:14 PM
Swartz RobinCOO&CBODec 23 '24Sale5.656,50036,725112,328Dec 26 04:29 PM
Swartz RobinOfficerDec 23 '24Proposed Sale5.656,50036,747Dec 23 11:31 AM
Fahey Sandell JacquelynChief Legal OfficerOct 02 '24Sale5.825,99934,91486,001Oct 03 04:43 PM
Fahey Sandell JacquelynOfficerOct 02 '24Proposed Sale5.825,99934,920Oct 02 04:26 PM
Swartz RobinChief Operating OfficerApr 02 '24Sale9.881,35713,407117,004Apr 03 04:13 PM
Sandrock AlfredPresident and CEOApr 02 '24Sale9.8612,115119,454322,839Apr 03 04:10 PM
Swartz RobinChief Operating OfficerFeb 21 '24Sale7.453,96629,547118,361Feb 22 04:36 PM
Sandrock AlfredPresident and CEOFeb 21 '24Sale7.4613,03397,226334,954Feb 22 04:34 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 21 '24Sale7.463,76428,079175,669Feb 22 04:32 PM
Carter Todd AlfredChief Scientific OfficerFeb 21 '24Sale7.473,36525,13787,627Feb 22 04:30 PM
Carter Todd AlfredChief Scientific OfficerFeb 20 '24Sale7.686024,62390,992Feb 22 04:30 PM